Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan, Via Pace 9, 20122 Milan, Italy.
Rheumatology (Oxford). 2012 Jan;51(1):52-9. doi: 10.1093/rheumatology/ker335. Epub 2011 Nov 15.
To determine the role of Class II HLAs in SSc patients from Italy and Spain and in SSc patients of Caucasian ancestry.
Nine hundred and forty-four SSc patients (Italy 392 patients; Spain 452 patients) and 1320 ethnically matched healthy controls (Italy 398 patients; Spain 922 patients) were genotyped up to the fourth digit by PCR with sequence-specific oligonucleotides for HLA-DRB1, DQA1 and DQB1 loci. Patients included 390 ACA-positive and 254 anti-topo I-positive subjects. Associations between SSc or SSc-specific antibodies and HLA alleles or HLA haplotypes were sought via the chi-square test after 10 000-fold permutation testing. A meta-analysis including this study cohort and other Caucasoids samples was also conducted.
In both the cohorts, the strongest association was observed between the HLA-DRB11104 allele and SSc or anti-topo I antibodies. The HLA-DRB11104 -DQA10501 -DQB10301 haplotype was overrepresented in Italian [odds ratio (OR) = 2.069, 95% asymptotic CIs (CI(95)) 1.486, 2.881; P < 0.001] and in Spanish patients (OR = 6.707, CI(95) 3.974, 11.319; P < 0.001) as well as in anti-topo-positive patients: Italy (OR = 2.642, CI(95) 1.78, 3.924; P < 0.001) and Spain (OR = 20.625, CI(95) 11.536, 36.876; P < 0.001). In both the populations we also identified an additional risk allele (HLA-DQB103) and a protective allele (HLA-DQB10501) in anti-topo-positive patients. The meta-analysis showed different statistically significant associations, the most interesting being the differential association between HLA-DRB1*01 alleles and ACAs (OR = 1.724, CI(95) 1.482, 2.005; P < 0.001) or topo I antibodies (OR = 0.5, CI(95) 0.384, 0.651; P < 0.001).
We describe multiple robust associations between SSc and HLA Class II antigens in Caucasoids that may help to understand the genetic architecture of SSc.
确定意大利和西班牙的 SSc 患者以及白种人 SSc 患者中 II 类 HLA 的作用。
944 名 SSc 患者(意大利 392 名患者;西班牙 452 名患者)和 1320 名匹配的健康对照者(意大利 398 名患者;西班牙 922 名患者)通过 PCR 与序列特异性寡核苷酸进行基因分型,达到第四位数字,用于 HLA-DRB1、DQA1 和 DQB1 基因座。患者包括 390 名 ACA 阳性和 254 名抗拓扑异构酶 I 阳性患者。通过 10000 次随机置换检验后,通过卡方检验寻找 SSc 或 SSc 特异性抗体与 HLA 等位基因或 HLA 单倍型之间的关联。还进行了一项荟萃分析,包括该研究队列和其他白种人群样本。
在两个队列中,与 HLA-DRB11104 等位基因与 SSc 或抗拓扑异构酶 I 抗体之间的关联最强。HLA-DRB11104-DQA10501-DQB10301 单倍型在意大利(比值比(OR)=2.069,95%渐近置信区间(CI(95))1.486,2.881;P<0.001)和西班牙患者中过度表达(OR=6.707,CI(95)3.974,11.319;P<0.001)以及抗拓扑异构酶 I 阳性患者中:意大利(OR=2.642,CI(95)1.78,3.924;P<0.001)和西班牙(OR=20.625,CI(95)11.536,36.876;P<0.001)。在两个群体中,我们还在抗拓扑异构酶 I 阳性患者中鉴定出了一个额外的风险等位基因(HLA-DQB103)和一个保护性等位基因(HLA-DQB10501)。荟萃分析显示出不同的统计学显著关联,最有趣的是 HLA-DRB1*01 等位基因与 ACA(OR=1.724,CI(95)1.482,2.005;P<0.001)或拓扑异构酶 I 抗体(OR=0.5,CI(95)0.384,0.651;P<0.001)之间的差异关联。
我们描述了白种人 SSc 与 HLA II 类抗原之间的多种稳健关联,这可能有助于理解 SSc 的遗传结构。